drugset / Trial / NCT01151059

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

NCT01151059

Phase 2 Completed 138 enrolled Novartis Vaccines
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The present study will evaluate the safety and immunogenicity in healthy people (non-elderly adult and elderly subjects) after one intramuscular (IM) dose of trivalent subunit inactivated flu vaccine.

Timeline

Start
2010-06
Primary completion
2010-06
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Agrippal S1 Vaccine Intramuscular

Indications